Vivos (RDGL) Invested Capital (2011 - 2023)

Vivos (RDGL) reported Invested Capital of $10000.0 for Q3 2023, down 75.0% sequentially from $40000.0 in Q1 2018.

Vivos (RDGL) Invested Capital (2011 - 2023) Analysis & Trends

Vivos (RDGL) has 9 years of Invested Capital data on file, last reported at $10000.0 in Q3 2023.

For the quarter ending Q3 2023, Invested Capital changed N/A year-over-year to $10000.0; the trailing twelve-month figure through Jun 2024 stood at $10000.0 (changed N/A YoY), and the FY2016 full-year result was $332195.0, down 74.06% from the prior year.
Invested Capital fell to $10000.0 in Q3 2023, from $40000.0 in the prior quarter.
In the past five years, Invested Capital ranged from a high of $10000.0 in Q3 2023 to a low of $10000.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Abbott Laboratories	182.32 Bn	175.02 Bn	6.27 Bn	4.41 Bn
2	Stryker	128.75 Bn	125.88 Bn	3.81 Bn	499.00 Mn
3	Medtronic	107.83 Bn	98.61 Bn	6.41 Bn	1.79 Bn
4	Boston Scientific	67.61 Bn	66.15 Bn	3.61 Bn	41.00 Mn
5	Edwards Lifesciences	48.13 Bn	44.45 Bn	1.29 Bn	-
6	Dexcom	28.26 Bn	27.14 Bn	750.30 Mn	-
7	GE HealthCare Technologies	27.78 Bn	25.50 Bn	1.98 Bn	7.00 Mn
8	Smith & Nephew	26.99 Bn	26.41 Bn	-	15.00 Mn
9	Koninklijke Philips	23.92 Bn	20.80 Bn	2.07 Bn	1.41 Bn
10	Vivos	27.16 Mn	25.60 Mn	-3,105.00	-

Download Data